Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/MUC1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MUC1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MUC1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MUC1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MUC1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MUC1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MUC1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MUC1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MUC1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MUC1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MUC1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MUC1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190179651 | Stomach | SIM | regulation of signal transduction by p53 class mediator | 11/708 | 93/18723 | 7.61e-04 | 1.07e-02 | 11 |
GO:00086304 | Stomach | SIM | intrinsic apoptotic signaling pathway in response to DNA damage | 11/708 | 99/18723 | 1.28e-03 | 1.59e-02 | 11 |
GO:003600311 | Stomach | SIM | positive regulation of transcription from RNA polymerase II promoter in response to stress | 5/708 | 24/18723 | 1.78e-03 | 2.01e-02 | 5 |
GO:00723324 | Stomach | SIM | intrinsic apoptotic signaling pathway by p53 class mediator | 9/708 | 76/18723 | 2.23e-03 | 2.30e-02 | 9 |
GO:19021652 | Stomach | SIM | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 4/708 | 16/18723 | 2.56e-03 | 2.54e-02 | 4 |
GO:000716221 | Stomach | SIM | negative regulation of cell adhesion | 22/708 | 303/18723 | 2.76e-03 | 2.69e-02 | 22 |
GO:190225321 | Stomach | SIM | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 5/708 | 29/18723 | 4.26e-03 | 3.79e-02 | 5 |
GO:00427715 | Stomach | SIM | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 6/708 | 43/18723 | 5.29e-03 | 4.41e-02 | 6 |
GO:00303305 | Stomach | SIM | DNA damage response, signal transduction by p53 class mediator | 8/708 | 72/18723 | 5.70e-03 | 4.67e-02 | 8 |
GO:2001233113 | Thyroid | PTC | regulation of apoptotic signaling pathway | 197/5968 | 356/18723 | 2.58e-20 | 3.69e-18 | 197 |
GO:0097193113 | Thyroid | PTC | intrinsic apoptotic signaling pathway | 164/5968 | 288/18723 | 9.17e-19 | 1.09e-16 | 164 |
GO:001657010 | Thyroid | PTC | histone modification | 235/5968 | 463/18723 | 1.17e-17 | 1.15e-15 | 235 |
GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
GO:2001242113 | Thyroid | PTC | regulation of intrinsic apoptotic signaling pathway | 99/5968 | 164/18723 | 4.74e-14 | 2.79e-12 | 99 |
GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
GO:2001234113 | Thyroid | PTC | negative regulation of apoptotic signaling pathway | 124/5968 | 224/18723 | 2.57e-13 | 1.32e-11 | 124 |
GO:00183947 | Thyroid | PTC | peptidyl-lysine acetylation | 99/5968 | 169/18723 | 6.54e-13 | 3.08e-11 | 99 |
GO:00064757 | Thyroid | PTC | internal protein amino acid acetylation | 92/5968 | 160/18723 | 1.80e-11 | 7.06e-10 | 92 |
GO:00183937 | Thyroid | PTC | internal peptidyl-lysine acetylation | 91/5968 | 158/18723 | 2.04e-11 | 7.91e-10 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MUC1 | SNV | Missense_Mutation | novel | c.640C>A | p.Pro214Thr | p.P214T | | protein_coding | tolerated(0.08) | possibly_damaging(0.503) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
MUC1 | SNV | Missense_Mutation | | c.1102N>T | p.Val368Phe | p.V368F | | protein_coding | deleterious(0.05) | benign(0.186) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
MUC1 | SNV | Missense_Mutation | novel | c.998C>A | p.Thr333Asn | p.T333N | | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-D8-A1XC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
MUC1 | deletion | Frame_Shift_Del | novel | c.643_697delNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Ala215ProfsTer100 | p.A215Pfs*100 | | protein_coding | | | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MUC1 | SNV | Missense_Mutation | rs759820018 | c.247N>G | p.Gln83Glu | p.Q83E | | protein_coding | tolerated(0.8) | benign(0.101) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MUC1 | SNV | Missense_Mutation | novel | c.620N>G | p.Ser207Cys | p.S207C | | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MUC1 | SNV | Missense_Mutation | novel | c.701N>G | p.Leu234Arg | p.L234R | | protein_coding | tolerated(0.37) | benign(0.299) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MUC1 | SNV | Missense_Mutation | novel | c.1183N>A | p.Leu395Met | p.L395M | | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MUC1 | SNV | Missense_Mutation | novel | c.854N>T | p.Ser285Phe | p.S285F | | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MUC1 | SNV | Missense_Mutation | novel | c.175G>A | p.Glu59Lys | p.E59K | | protein_coding | tolerated(0.48) | possibly_damaging(0.497) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Anti-MUC1 mab | | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | G0-203-2c | | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | SODIUM BUTYRATE | | 2211839 |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | MUC-1 CART cell immunotherapy | | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | Pankomab-GEX | | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | BREVAREX MAB | | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AS-1402 | HUHMFG1 | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | SAR-566658 | SAR-566658 | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | GO-203-2c | GO-203-2C | |
4582 | MUC1 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | | AS1402 | HUHMFG1 | |